Multiplex Assay Kit for C1q And Tumor Necrosis Factor Related Protein 9 (C1QTNF9) ,etc. by FLIA (Flow Luminescence Immunoassay) 
CTRP9; C1QTNF9A; AQL1; Complement C1q and tumor necrosis factor-related protein 9A
(Note: Up to 8-plex in one testing reaction)
- UOM
- FOB US$ 480.00 US$ 499.00 US$ 527.00 US$ 564.00 US$ 601.00 US$ 656.00 US$ 739.00 US$ 924.00
- Quantity
Overview
Properties
- Product No.LMR877Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryTumor immunity
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
Results demonstration
-
Typical Standard Curve
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant C1q And Tumor Necrosis Factor Related Protein 9 (C1QTNF9) and the recovery rates were calculated by comparing the measured value to the expected amount of C1q And Tumor Necrosis Factor Related Protein 9 (C1QTNF9) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 78-105 | 83 |
| EDTA plasma(n=5) | 91-98 | 95 |
| heparin plasma(n=5) | 78-91 | 82 |
| sodium citrate plasma(n=5) | 82-91 | 86 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level C1q And Tumor Necrosis Factor Related Protein 9 (C1QTNF9) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level C1q And Tumor Necrosis Factor Related Protein 9 (C1QTNF9) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of C1q And Tumor Necrosis Factor Related Protein 9 (C1QTNF9) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 95-105% | 85-93% | 78-93% | 81-94% |
| EDTA plasma(n=5) | 94-103% | 91-105% | 91-99% | 83-94% |
| heparin plasma(n=5) | 87-94% | 97-105% | 81-104% | 80-96% |
| sodium citrate plasma(n=5) | 97-105% | 97-105% | 95-103% | 81-101% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:C1QTNF9) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Add 200μL analysis buffer solution to each well of the plate for pre-wetting;
2. Preparation of standards, reagents and samples before the experiment;
3. Add 100μL standard or sample to each well, add 10μL magnetic beads, and incubate 120 minutes protect from light at 25°C on shaker;
4. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60 minutes protect from light at 25°C on shaker;
5. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent B, and incubate 30 minutes protect from light at 25°C on shaker;
6. Wash plate once on magnetic frame;
7. Add 100μL sheath fluid, swirl for 10 minutes, read on the machine.
Test principle
Anti-C1q And Tumor Necrosis Factor Related Protein 9 (C1QTNF9) antibody was coated on the surface of magnetic beads, to make solid phase carrier. Standard or sample were added to the magnetic beads, respectively, in which C1q And Tumor Necrosis Factor Related Protein 9 (C1QTNF9) was bound to the antibody connected to the solid phase carrier, and then biotinylated anti-C1q And Tumor Necrosis Factor Related Protein 9 (C1QTNF9) antibodies were added. PE-labeled avidin was added. There is a positive correlation between the concentration of C1q And Tumor Necrosis Factor Related Protein 9 (C1QTNF9) in the sample and corresponding value of MFI (Median Fluorescence Intensity).
Giveaways
Increment services
Citations
- Association of serum C1q/TNF-Related Protein-9 (CTRP9) concentration with visceral adiposity and metabolic syndrome in humans.Pubmed: 24357853
- Association of Serum C1q/TNF-Related Protein-9 Concentration With Arterial Stiffness in Subjects With Type 2 DiabetesPubmed:25105737
- C1q/TNF-Related Protein-9 (CTRP9) Levels Are Associated With Obesity and Decrease Following Weight Loss SurgeryPubmed:26982010
- Circulating C1q complement/TNF-related protein (CTRP) 1, CTRP9, CTRP12 and CTRP13 concentrations in Type 2 diabetes mellitus: In vivo regulation by glucose.pubmed:28207876
- Plasma C1q/TNF-Related Protein-9 Levels Are Associated with Atherosclerosis in Patients withType 2 Diabetes without Renal Dysfunction.pubmed:28070523
- Circulating CTRP9 levels are increased in patients with newly diagnosed type 2 diabetes and correlated with insulin resistancepubmed:28743061
- Association of circulating CTRP9 with soluble adhesion molecules and inflammatory markers in patients with type 2 diabetes mellitus and coronary artery …Pubmed:29381773
- Effect of a single bout of resistance exercise on zinc-α2-glycoproteinPubmed: 31686532
- Association of serum CTRP9 levels with cardiac autonomic neuropathy in patients with type 2 diabetes mellitus33417302
- Association Between Serum C1q Tumor Necrosis Factor-Related Protein 9 and the Clinical Characteristics and Prognosis of Ischemic Stroke34727346